CureVac AG Price, Forecast, Insider, Ratings, Fundamentals & Signals

TÜbingen, germany and boston, ma / accesswire / april 18, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), will report financial results, and provide business updates for the fourth quarter and full-year 2023 on wednesday, april 24, 2024.

Agreement creates strong synergies between curevac's unique end-to-end mrna capabilities and md anderson's translational and clinical research expertise collaboration aims to develop novel, off-the-shelf, mrna-based cancer vaccines in selected hematological and solid cancers with high unmet medical need md anderson responsible for leading initial phase 1/2 studies; curevac retains worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates tÜbingen, germany and houston, tx / accesswire / april 16, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), and the university of texas md anderson cancer center today announced a co-development and licensing agreement to develop novel mrna-based cancer vaccines.

Potentially differentiated, multivalent candidate encodes antigens matched to all four who-recommended flu strains for influenza a strains, geometric mean titers numerically exceeded those elicited by the licensed comparator vaccines consistently across all tested dose levels and age groups for influeseasonal flu vaccine candidate boosted antibody titers at all dose levels and for all encoded seasonal influenza strains across younger and older adults nza b strains, geometric mean titers were lower than those elicited by the licensed comparator vaccines, in line with expectations and other initial mrna-based clinical flu development programs further optimizations to enhance immune responses against influenza b strains will be tested in additional phase 2 study candidate showed acceptable safety profile, confirming previous findings that the proprietary platform elicits strong overall antibody titers at well-tolerated dose levels tÜbingen, germany and boston, ma / accesswire / april 4, 2024 / curevac n...

Head-to-head comparison with licensed bivalent mrna-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile monovalent mrna vaccine candidate, cv0601, encoding omicron ba.4-5 variant and bivalent candidate, cv0701, encoding omicron ba.4-5 variant as well as the original sars-cov-2 virus, successfully boosted antibody titers and were generally well tolerated across all tested dose levels tÜbingen, germany and boston, ma / accesswire / january 5, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced positive interim data from the ongoing phase 2 study assessing monovalent and bivalent modified vaccine candidates against covid-19.

Validity of curevac patent ep 1 857 122 b1 denied by german federal patent court after nullity action filed by biontech se decision does not affect ongoing litigation in germany regarding seven other intellectual property rights, covering strong foundational as well as covid-19-specific mrna innovation curevac to appeal before the german federal court of justice, while remaining confident in the strength of its broad intellectual property portfolio tÜbingen, germany and boston, ma / accesswire / december 19, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the nullity action filed by biontech se against the german part of curevac patent ep 1 857 122 b1 was granted by the german federal patent court.

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2023 on Wednesday, April 24, 2024.

CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

The heavy selling pressure might have exhausted for CureVac N.V. (CVAC) as it is technically in oversold territory now.

CureVac N.V. (NASDAQ:CVAC ) Q3 2023 Earnings Conference Call November 14, 2023 9:00 AM ET Company Participants Sarah Fakih - VP, Corporate Communications and IR Alexander Zehnder - CEO Pierre Kemula - CFO Myriam Mendila - CDO Marcus Dalton - Head, Intellectual Property Conference Call Participants Evan Wang - Guggenheim Ellie Merle - UBS Eun Yang - Jefferies Charlie Yang - Bank of America Operator Greetings and welcome to the CureVac Financial Results for Third Quarter and First Nine Months of 2023 Business Update.

CureVac previously failed to develop a successful COVID-19 vaccine, but filed a lawsuit last year against BioNTech alleging intellectual property violations. On Thursday a German court paused proceedings in the lawsuit while it awaits the outcome of BioNTech's challenge to the validity of that IP.

CureVac NV CVAC, -3.85% said Tuesday that it has selected an mRNA flu vaccine candidate for continued clinical development, based on positive results from an early-stage study conducted in collaboration with GSK PLC GSK, +1.29%. The investigational vaccine provides broad antigen coverage against flu strains recommended by the World Health Organization and will advance to a phase 2 study, with dosing of the first study participant expected in the fourth quarter of this year, the company said in a release.

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting scheduled for September 12, 2023.

CureVac has an ongoing collaboration with GlaxoSmithKline. It just launched the first clinical study of a vaccine using CureVac's next-generation mRNA platform.

The European biotech delivered some promising news from the laboratory. It has dosed its first patient in a crucial phase 1 trial of its cancer vaccine.

The Boston-based fund has emerged as a force to be reckoned with in the world of biotech investments.